The Food and Drug Administration (FDA) has approved Breo Ellipta (fluticasone furoate/vilanterol) for the once-daily treatment of asthma in patients aged 18 years and older. The approval of the ...

BREO ELLIPTA (fluticasone furoate and vilanterol) Inhalation Powder Breo Ellipta (fluticasone furoate/vilanterol; GlaxoSmithKline and Theravance) has been made available for chronic obstructive ...

GlaxoSmithKline’s new long-term, once-daily, maintenance therapy for chronic obstructive pulmonary disease (COPD) has been approved in the US. The FDA licensed Breo Ellipta to treat airflow ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday approved Breo Ellipta for the once-daily treatment of asthma in adults, according to a ...

WASHINGTON (AP) -- The Food and Drug Administration says it has approved a new once-a-day inhaler drug from GlaxoSmithKline for patients with chronic lung disease. The agency cleared the Breo Ellipta ...

WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...

LONDON—A large clinical trial run by GlaxoSmithKline PLCGSK0.75%increase; green up pointing triangle has failed to show that the company’s Breo Ellipta inhaler extends life in patients with chronic ...

Breo Ellipta inhaler cleared for long-term use Breo Ellipta delivers a combination of two drugs Drug not approved for asthma treatment WASHINGTON (AP) — The Food and Drug Administration says it has ...

Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ®, ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 30, 2015) - GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug ...